Navigating Continuous Disclosure: The Research Analyst’s Ongoing Compliance Burden
Imagine you are tracking a mid-cap pharmaceutical stock. You have just finalized a bullish report based on their recent patent approvals, but halfway through your analysis, the company announces a change in their...